Kimberly Hedlin

MediPharm Labs Corp. (OTC: MLCPF) discounted cash flow-derived per-share value is increasing, according to Canaccord Genuity.  The Analyst Kimberly Hedlin reiterated a Speculative Buy rating on MediPharm and raised the price target from CA$4.75 to CA$5.50. The Thesis Confidence surrounding...